184 related articles for article (PubMed ID: 20508670)
1. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.
Grandi P; Fernandez J; Szentirmai O; Carter R; Gianni D; Sena-Esteves M; Breakefield XO
Cancer Gene Ther; 2010 Sep; 17(9):655-63. PubMed ID: 20508670
[TBL] [Abstract][Full Text] [Related]
2. HSV-1 virions engineered for specific binding to cell surface receptors.
Grandi P; Wang S; Schuback D; Krasnykh V; Spear M; Curiel DT; Manservigi R; Breakefield XO
Mol Ther; 2004 Mar; 9(3):419-27. PubMed ID: 15006609
[TBL] [Abstract][Full Text] [Related]
3. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.
Kuan CT; Wikstrand CJ; Archer G; Beers R; Pastan I; Zalutsky MR; Bigner DD
Int J Cancer; 2000 Dec; 88(6):962-9. PubMed ID: 11093822
[TBL] [Abstract][Full Text] [Related]
4. Targeting human glioma cells using HSV-1 amplicon peptide display vector.
Ho IA; Miao L; Sia KC; Wang GY; Hui KM; Lam PY
Gene Ther; 2010 Feb; 17(2):250-60. PubMed ID: 19812609
[TBL] [Abstract][Full Text] [Related]
5. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread.
Laquerre S; Argnani R; Anderson DB; Zucchini S; Manservigi R; Glorioso JC
J Virol; 1998 Jul; 72(7):6119-30. PubMed ID: 9621076
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells.
Mårdberg K; Trybala E; Tufaro F; Bergström T
J Gen Virol; 2002 Feb; 83(Pt 2):291-300. PubMed ID: 11807221
[TBL] [Abstract][Full Text] [Related]
7. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
8. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism.
Gerber SI; Belval BJ; Herold BC
Virology; 1995 Dec; 214(1):29-39. PubMed ID: 8525631
[TBL] [Abstract][Full Text] [Related]
9. Bovine herpesvirus 1 glycoprotein B does not productively interact with cell surface heparan sulfate in a pseudorabies virion background.
Klupp BG; Karger A; Mettenleiter TC
J Virol; 1997 Jun; 71(6):4838-41. PubMed ID: 9151882
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B.
Herold BC; Visalli RJ; Susmarski N; Brandt CR; Spear PG
J Gen Virol; 1994 Jun; 75 ( Pt 6)():1211-22. PubMed ID: 8207388
[TBL] [Abstract][Full Text] [Related]
11. Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma.
Appolloni I; Alessandrini F; Menotti L; Avitabile E; Marubbi D; Piga N; Ceresa D; Piaggio F; Campadelli-Fiume G; Malatesta P
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578259
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry.
Bender FC; Whitbeck JC; Lou H; Cohen GH; Eisenberg RJ
J Virol; 2005 Sep; 79(18):11588-97. PubMed ID: 16140736
[TBL] [Abstract][Full Text] [Related]
13. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo.
Tiwari V; Liu J; Valyi-Nagy T; Shukla D
J Biol Chem; 2011 Jul; 286(28):25406-15. PubMed ID: 21596749
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of HSV-1 cell-free virion release by the envelope protein gC.
Frost TC; Salnikov M; Rice SA
Virology; 2024 Aug; 596():110120. PubMed ID: 38805801
[TBL] [Abstract][Full Text] [Related]
15. Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C.
Feyzi E; Trybala E; Bergström T; Lindahl U; Spillmann D
J Biol Chem; 1997 Oct; 272(40):24850-7. PubMed ID: 9312084
[TBL] [Abstract][Full Text] [Related]
16. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
18. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
19. Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry.
Herold BC; Gerber SI; Belval BJ; Siston AM; Shulman N
J Virol; 1996 Jun; 70(6):3461-9. PubMed ID: 8648678
[TBL] [Abstract][Full Text] [Related]
20. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells.
Laquerre S; Anderson DB; Stolz DB; Glorioso JC
J Virol; 1998 Dec; 72(12):9683-97. PubMed ID: 9811702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
